Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.

The research article revolves around the study of horse drug metabolism, specifically investigating the role of the CYP2D family, as it’s hypothesized to affect metabolic rates and susceptibility to various drugs in horses. The study uses codeine, a drug that is metabolically processed by the CYP2D6 enzyme, to study the metabolic behavior in horses.

Study Approach and Findings

• The main approach involved using varying concentrations of codeine and then incubating it with equine liver microsomes (a type of cellular structure in horses) and a panel of baculovirus expressed recombinant equine P450s (a type of enzyme).
• The post-incubation results showed the generation of norcodeine, morphine, and other derivatives, suggesting that these substances might have played a role in the metabolism of codeine.
• The newly identified enzyme, CYP2D82, was observed to effectively convert codeine to morphine, which is an important metabolic transformation. Its efficiency was quantified at certain values of K and V.
• It’s worth noting that CYP2D82 shows 80% similarity to the human enzyme CYP2D6 that handles the same conversion.
• The study also observed the roles of CYP3A95 and CYP2D50 in converting codeine to norcodeine. These enzymes similarly shared a degree of homology to their human equivalent, CYP3A4.

Significance and Implications

• The research provides valuable insights into the metabolic processing of drugs in horses. Codeine has also emerged as a useful tool for understanding variations in the CYP2D gene in horses, which is valuable information for veterinary pharmacologists and researchers focusing on equine health and medication.
• Understanding these metabolic pathways will help in predicting drug responses in horses, which is a key factor in effective administration and dosage determination of therapeutic drugs. This is especially important given the value of horses as sport and companion animals, and due to the wide differences in individual pharmacokinetics.